JP2020504157A - Ｃ−ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物 - Google Patents

Ｃ−ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物 Download PDF

Info

Publication number
JP2020504157A
JP2020504157A JP2019537845A JP2019537845A JP2020504157A JP 2020504157 A JP2020504157 A JP 2020504157A JP 2019537845 A JP2019537845 A JP 2019537845A JP 2019537845 A JP2019537845 A JP 2019537845A JP 2020504157 A JP2020504157 A JP 2020504157A
Authority
JP
Japan
Prior art keywords
aki
assay
subject
threshold
persistent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019537845A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504157A5 (enExample
Inventor
ジェイムズ パトリック カンプ，
ジェイムズ パトリック カンプ，
ポール マクファーソン，
ポール マクファーソン，
ドナルド チャルフィン，
ドナルド チャルフィン，
Original Assignee
アスチュート メディカル，インコーポレイテッド
アスチュート メディカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスチュート メディカル，インコーポレイテッド, アスチュート メディカル，インコーポレイテッド filed Critical アスチュート メディカル，インコーポレイテッド
Publication of JP2020504157A publication Critical patent/JP2020504157A/ja
Publication of JP2020504157A5 publication Critical patent/JP2020504157A5/ja
Priority to JP2022044473A priority Critical patent/JP2022091846A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2019537845A 2017-01-12 2018-01-12 Ｃ−ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物 Pending JP2020504157A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022044473A JP2022091846A (ja) 2017-01-12 2022-03-18 Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762445692P 2017-01-12 2017-01-12
US62/445,692 2017-01-12
PCT/US2018/013561 WO2018132702A1 (en) 2017-01-12 2018-01-12 Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022044473A Division JP2022091846A (ja) 2017-01-12 2022-03-18 Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2020504157A true JP2020504157A (ja) 2020-02-06
JP2020504157A5 JP2020504157A5 (enExample) 2021-03-18

Family

ID=62840533

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537845A Pending JP2020504157A (ja) 2017-01-12 2018-01-12 Ｃ−ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物
JP2022044473A Pending JP2022091846A (ja) 2017-01-12 2022-03-18 Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022044473A Pending JP2022091846A (ja) 2017-01-12 2022-03-18 Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物

Country Status (8)

Country Link
US (2) US11353465B2 (enExample)
EP (2) EP4063853A1 (enExample)
JP (2) JP2020504157A (enExample)
CN (2) CN110651187A (enExample)
AU (1) AU2018207151B2 (enExample)
CA (1) CA3049444A1 (enExample)
MX (1) MX2019008260A (enExample)
WO (1) WO2018132702A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022091846A (ja) * 2017-01-12 2022-06-21 アスチュート メディカル，インコーポレイテッド Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物
JP2025507789A (ja) * 2022-03-03 2025-03-21 アスチュート メディカル，インコーポレイテッド Ｃ－ｃモチーフケモカインリガンド１４測定に基づいて持続性急性腎障害を評価及び処置するための方法及び組成物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3732196A4 (en) 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND ASSAYS FOR CCL14
US20220236285A1 (en) * 2019-05-24 2022-07-28 Astute Medical, Inc. Methods for evaluation and treatment of renal injury based on c-c motif chemokine ligand 14 measurement
AU2020300544B2 (en) * 2019-07-02 2024-07-25 Astute Medical, Inc Antibodies and assays for CCL14
AU2021381364A1 (en) * 2020-11-18 2023-06-22 Astute Medical, Inc. Methods and compositions for treatment of renal injury and renal failure
CN113555122B (zh) * 2021-07-21 2024-04-26 中南大学湘雅二医院 一种重症脓毒症患者一过性和持续性aki的预测模型及其构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016064877A2 (en) * 2014-10-20 2016-04-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6811773B1 (en) * 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20030157573A1 (en) 2002-02-12 2003-08-21 Orna Mor Use of Axl receptor for diagnosis and treatment of renal disease
US7833732B2 (en) 2005-07-21 2010-11-16 The John Hopkins University Acute renal injury
EP2479568B1 (en) 2007-03-26 2015-01-07 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
US9057735B2 (en) 2008-08-29 2015-06-16 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104020284B (zh) 2008-10-21 2016-08-24 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP2462443A4 (en) 2009-08-07 2013-01-30 Rules Based Medicine Inc METHODS AND DEVICES FOR DETECTING GLOMERULONEPHRITH AND ASSOCIATED DISORDERS
MX2012005210A (es) 2009-11-07 2012-08-03 Astute Medical Inc Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.
US20120156701A1 (en) 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) * 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
DK2666872T3 (en) 2010-02-05 2016-07-25 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103080743B (zh) 2010-06-23 2015-07-22 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US20130203074A1 (en) 2010-06-23 2013-08-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9410968B2 (en) * 2011-04-04 2016-08-09 Universiteit Gent Biomarkers for acute kidney injury
ES2721907T3 (es) 2011-08-26 2019-08-06 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013096740A1 (en) 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
EP4063853A1 (en) 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016064877A2 (en) * 2014-10-20 2016-04-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022091846A (ja) * 2017-01-12 2022-06-21 アスチュート メディカル，インコーポレイテッド Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物
JP2025507789A (ja) * 2022-03-03 2025-03-21 アスチュート メディカル，インコーポレイテッド Ｃ－ｃモチーフケモカインリガンド１４測定に基づいて持続性急性腎障害を評価及び処置するための方法及び組成物

Also Published As

Publication number Publication date
US11353465B2 (en) 2022-06-07
EP4063853A1 (en) 2022-09-28
JP2022091846A (ja) 2022-06-21
US20230025225A1 (en) 2023-01-26
CN110651187A (zh) 2020-01-03
US20190339289A1 (en) 2019-11-07
CA3049444A1 (en) 2018-07-19
US12203944B2 (en) 2025-01-21
EP3568695A4 (en) 2020-12-16
EP3568695A1 (en) 2019-11-20
AU2018207151A1 (en) 2019-07-18
AU2018207151B2 (en) 2024-02-29
MX2019008260A (es) 2020-01-27
WO2018132702A1 (en) 2018-07-19
CN114088950A (zh) 2022-02-25

Similar Documents

Publication Publication Date Title
JP6309434B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN105074466B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102439441B (zh) 用于肾损伤和肾衰竭的诊断及预后方法和组合物
JP7217796B2 (ja) 腎障害および腎不全の診断および予後のための方法および組成物
US12203944B2 (en) Methods and compositions for evaluation and treatment of renal injury and renal failure based on C-C motif chemokine ligand 14 measurement
HK1212764A1 (zh) 用於肾损伤和肾衰竭的诊断及预後的方法和组合物
CN103874923A (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
HK1200218A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1220764A1 (zh) 肾损伤和肾衰竭的诊断及预後
HK1212770A1 (zh) 用於腎損傷和腎衰竭的診斷及預後的方法和組合物
CN103858008B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN105209914B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN107709993A (zh) 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
HK1195127A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1203620B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1167455B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1203620A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1195128A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1168129B (en) Diagnosis and prognosis of renal injury and renal failure
HK1195128B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1171260B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200121

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220712